Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Karen L. Reckamp et al.|New England Journal of Medicine|2020Cited by 835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Paul K. Paik, Jeffrey W. Clark et al.|Nature Medicine|2020Cited by 393
ROS1-dependent cancers — biology, diagnostics and therapeuticsAlexander Drilon, Monika A. Davare, Chelsea Jenkins et al.|Nature Reviews Clinical Oncology|2020Cited by 288